(Albany, US) DelveInsight has launched a new report on “Hypertriglyceridemia – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Hypertriglyceridemia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Hypertriglyceridemia, historical and forecasted epidemiology as well as the Hypertriglyceridemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the Facts
- In the National Health and Nutrition Examination Survey (NHANES), from 1999 to 2004, about a third of participants had serum triglycerides above 150 mg/dL. In subjects aged 60 years or older, the prevalence was 42%, and 2% of subjects with hypertriglyceridemia had triglycerides of more than 500 mg/dL.
- According to Karanchi et al. (2019), the incidence of hypertriglyceridemia also varies by race, with a higher incidence observed in Hispanic-Americans and Asian-Indians, and lower incidence in African-Americans who generally have lower triglyceride levels. In addition, severe hypertriglyceridemia is the third leading cause of pancreatitis in the United States.
- The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) defined elevated triglycerides as 150 mg/dL and higher. Using that criterion, the Third National Health and Nutrition Examination Survey (NHANES) found that the prevalence of hypertriglyceridemia in US adults aged 20 years and older was approximately 35% in men and 25% in women.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/hypertriglyceridemia-market
Scope of the Report
- The report covers the descriptive overview of Hypertriglyceridemia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Hypertriglyceridemia epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Hypertriglyceridemia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Hypertriglyceridemia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hypertriglyceridemia market
Request for Free Sample Report: https://www.delveinsight.com/sample-request/hypertriglyceridemia-market
Hypertriglyceridemia refers to a fasting plasma triglyceride measurement that is increased, typically above the 95th percentile for age and sex along with additional quantitative or qualitative lipoprotein abnormalities. Patients can fluctuate between hypertriglyceridemic states: given appropriate metabolic stress, mild or moderate hypertriglyceridemia can deteriorate into severe hypertriglyceridemia.
The two main sources of plasma triglycerides (also known as triacylglycerol) are exogenous (i.e., from dietary fat)— carried in chylomicrons, and endogenous (from the liver)—carried in very-low-density lipoprotein (VLDL) particles.
HTG can be divided into primary and secondary types. In primary HTG, chylomicrons normally are cleared rapidly from plasma by lipoprotein lipase with apolipoprotein (apo) C-II as a cofactor—familial chylomicronemia (hyperlipoproteinemia type 1, in the Fredrickson system) and primary mixed hyperlipidemia (type 5) are each characterized by the pathologic presence of chylomicrons after a 12–14 h period of fasting—whereas, in secondary HTG, obesity is probably the metabolic stressor most frequently associated with hypertriglyceridemia, although associations with poorly controlled type 2 diabetes and excessive alcohol consumption are also common (associated with a secondary cause/acquired).
Request for Free Sample Report: https://www.delveinsight.com/sample-request/hypertriglyceridemia-market
Drugs Covered:
- Epanova (omega-3-carboxylic acids)
- Vascepa
- Lovaza (omega-3-acid ethyl esters)
- Evinacumab
- CaPre
- And Many Others
Some of the Companies:
- AstraZeneca
- Amarin Pharma Inc.
- GlaxoSmithKline
- Regeneron Pharmaceuticals
- Acasti Pharma
- Kowa Research Institute, Inc.
- And Many Others
Table of Contents:
1. Key Insights
2. Executive Summary of Hypertriglyceridemia
3. Competitive Intelligence Analysis for Hypertriglyceridemia
4. Hypertriglyceridemia: Market Overview at a Glance
5. Hypertriglyceridemia: Disease Background and Overview
6. Patient Journey
7. Hypertriglyceridemia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Hypertriglyceridemia Treatment
11. Marketed Products
12. Emerging Therapies
13. Hypertriglyceridemia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Hypertriglyceridemia
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/hypertriglyceridemia-market
Why should you buy this report?
- The report will help in developing business strategies by understanding trends shaping and driving the Hypertriglyceridemia market
- To understand the future market competition in the Hypertriglyceridemia market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Hypertriglyceridemia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Hypertriglyceridemia market
- To understand the future market competition in the Hypertriglyceridemia market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/hypertriglyceridemia-market